Published in Biochem Mol Biol Educ on July 01, 2010
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med (2002) 4.89
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
A comprehensive survey of Ras mutations in cancer. Cancer Res (2012) 3.67
Pedagogies of engagement in science: A comparison of PBL, POGIL, and PLTL* Biochem Mol Biol Educ (2008) 3.40
Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics (2009) 3.00
Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. BMJ (2012) 2.66
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr (2010) 2.59
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (2006) 2.35
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis (2012) 1.76
Allosteric modulation of Ras positions Q61 for a direct role in catalysis. Proc Natl Acad Sci U S A (2010) 1.62
When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS (2003) 1.60
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol (2012) 1.55
Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. J Infect (2010) 1.49
Achieving compliance with the European Working Time Directive in a large teaching hospital: a strategic approach. Clin Med (2004) 1.49
The changing pattern of bronchoscopy in an HIV-infected population. Chest (2002) 1.42
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther (2008) 1.41
Iatrogenic effects of group treatment for antisocial youths. J Consult Clin Psychol (2005) 1.41
Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection. AIDS (2003) 1.41
Symptoms are highly prevalent among HIV outpatients and associated with poor adherence and unprotected sexual intercourse. Sex Transm Infect (2010) 1.40
A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis. Biochem J (2009) 1.33
Suicidal ideation in UK HIV clinic attenders. AIDS (2008) 1.31
Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf. Structure (2007) 1.26
Data linkage reduces loss to follow-up in an observational HIV cohort study. J Clin Epidemiol (2010) 1.26
Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS (2008) 1.23
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.23
Analysis of binding site hot spots on the surface of Ras GTPase. J Mol Biol (2011) 1.22
Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther (2008) 1.21
Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 1.20
Long-term trends in adherence to antiretroviral therapy from start of HAART. AIDS (2010) 1.17
Comparative evaluation of the ExaVir Load version 3 reverse transcriptase assay for measurement of human immunodeficiency virus type 1 plasma load. J Clin Microbiol (2009) 1.15
Role of loop bundle hydrogen bonds in the maturation and activity of (Pro)caspase-3. Biochemistry (2006) 1.12
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS (2008) 1.11
The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008. PLoS One (2011) 1.09
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS (2009) 1.09
Foundational concepts and underlying theories for majors in "biochemistry and molecular biology". Biochem Mol Biol Educ (2013) 1.09
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS (2008) 1.07
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica (2009) 1.07
Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc (2013) 1.07
Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS (2010) 1.05
Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity. AIDS Care (2008) 1.05
What factors are associated with patient self-reported health status among HIV outpatients? A multi-centre UK study of biomedical and psychosocial factors. AIDS Care (2012) 1.04
Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy. J Bone Miner Res (2013) 1.03
Structural mechanism of oxidative regulation of the phosphatase Cdc25B via an intramolecular disulfide bond. Biochemistry (2005) 1.03
Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors. PLoS One (2011) 1.02
Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS (2008) 1.02
Patient understanding of moles and skin cancer, and factors influencing presentation in primary care: a qualitative study. BMC Fam Pract (2010) 1.00
Economic analysis of combined endoscopic and endobronchial ultrasound in the evaluation of patients with suspected non-small cell lung cancer. Lung Cancer (2009) 0.99
Crystal structures of Ral-GppNHp and Ral-GDP reveal two binding sites that are also present in Ras and Rap. Structure (2004) 0.99
Successive switching of antiretroviral therapy is associated with high psychological and physical burden. Int J STD AIDS (2007) 0.98
Allosteric modulation of Ras-GTP is linked to signal transduction through RAF kinase. J Biol Chem (2010) 0.98
What skills should students of undergraduate biochemistry and molecular biology programs have upon graduation? Biochem Mol Biol Educ (2013) 0.98
The 'Antiretrovirals, Sexual Transmission Risk and Attitudes' (ASTRA) study. Design, methods and participant characteristics. PLoS One (2013) 0.96
Rising population cost for treating people living with HIV in the UK, 1997-2013. PLoS One (2010) 0.96
Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother (2010) 0.96
Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS (2004) 0.96
Novel method for visualizing and modeling the spatial distribution of neural stem cells within intracranial glioma. Neuroimage (2007) 0.96
Organic solvents order the dynamic switch II in Ras crystals. Structure (2003) 0.95
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS (2005) 0.95
Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol (2007) 0.95
Introduction to late presentation for HIV treatment in Europe. Antivir Ther (2010) 0.94
Impaired antigen-specific CD4(+) T lymphocyte responses in cavitary tuberculosis. Tuberculosis (Edinb) (2008) 0.94
CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy. AIDS (2002) 0.94
Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3. J Acquir Immune Defic Syndr (2008) 0.93
Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006. PLoS One (2011) 0.93
Essential concepts and underlying theories from physics, chemistry, and mathematics for "biochemistry and molecular biology" majors. Biochem Mol Biol Educ (2013) 0.93
Protocol for the MoleMate UK Trial: a randomised controlled trial of the MoleMate system in the management of pigmented skin lesions in primary care [ISRCTN 79932379]. BMC Fam Pract (2010) 0.92
Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation. Antivir Ther (2010) 0.92
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS (2007) 0.91
Multiple solvent crystal structures of ribonuclease A: an assessment of the method. Proteins (2009) 0.91
Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr (2008) 0.91
Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis. PLoS One (2011) 0.91
Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. J Virol (2003) 0.90
Mitochondrial fatty acid beta-oxidation in the retinal pigment epithelium. Pediatr Res (2002) 0.90
'Pathway drug cocktail': targeting Ras signaling based on structural pathways. Trends Mol Med (2013) 0.89
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730. AIDS Res Hum Retroviruses (2010) 0.88
Organelle and translocatable forms of glyoxysomal malate dehydrogenase. The effect of the N-terminal presequence. FEBS J (2005) 0.88
Clinical and behavioural aspects of aging with HIV infection. Psychol Health Med (2009) 0.87
Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Antivir Ther (2004) 0.87
Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men. J Acquir Immune Defic Syndr (2014) 0.87
Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy. AIDS (2014) 0.87
Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load. Intervirology (2012) 0.87
Behavioral surveillance study: sexual risk taking behaviour in UK HIV outpatient attendees. AIDS Behav (2012) 0.86
The impact of HIV drug resistance testing on changes to treatment. AIDS (2011) 0.84
A transformative model for undergraduate quantitative biology education. CBE Life Sci Educ (2010) 0.84
Allosteric modulation of caspase 3 through mutagenesis. Biosci Rep (2012) 0.84
Rapid folding and unfolding of Apaf-1 CARD. J Mol Biol (2007) 0.83
Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: the experience of London HIV commissioners and providers. Sex Transm Infect (2012) 0.83
Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. AIDS (2014) 0.82
Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification. PLoS Med (2012) 0.82